Skip to main content
Equibles
USAQ logo

USAQ · QHSLab, Inc.

Track USAQ — free

Use USAQ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research USAQ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.39 At close · Oct 21
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Despite the extinguishment of much of the Company's debt, the Company's history of losses combined with the amount of its revenues, raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$4.81M
Shares
15.03M
Volume · Oct 21 304 Avg daily vol (3M) 5684

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.39 Open$0.30 Day$0.30–0.47 52W close$0.16–0.92 Avg vol 30d6K Short int902 · 0.0% float · 1.0d Short vol33% DataJan 2020–Oct 2026 Filing10-Q · Aug 12

Up next

Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3.02M
Trailing 12 months
Net income (TTM)
−$390,726
Trailing 12 months
Revenue growth YoY
+40.0%
Year over year
Operating margin
2.7%
Trailing 12 months
P / E (TTM)
10.7
Trailing earnings · reciprocal yield 9.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+104.6%
Year over year · more shares
Price change (1Y)
+68.4%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
▲61.8% $544,285 $49,765 '24 Q3 ▲98.7% $625,981 −$287,589 '24 Q4* ▲32.1% $645,419 −$79,609 '25 Q1 ▲28% $605,446 −$52,958 '25 Q2 ▲35.4% $737,066 $33,411 '25 Q3 ▲12.4% $703,810 −$358,261 '25 Q4* ▲12.9% $728,685 −$103,906 '26 Q1 LATEST ▲40% $847,490 $38,030 '26 Q2

* Q4 derived as the full year minus Q1 to Q3.

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 16.7 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg +15%
above
RSI (14) 53
neutral
MACD trend Positive
52-week position 30%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +11%
trailing
6-month return +18%
trailing
YTD return −36%
this year
Relative strength +10%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.01% of float · ▲ +197.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 36
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 246%
annualized · 1-yr
Max drawdown −75%
past year
ATR 17.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
+15% Bullish
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
30% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.01% of float · ▲ +197.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0 Now $0 · 30% Range high $1
vs 200-day avg -6% vs 50-day avg +15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
USAQ
QHSLab, Inc.
this stock
$4.81M -35.9% +26.3% — 0.0%
ABT
Abbott Laboratories
 $171.24B -19.8% +5.7% 31.8 0.8%
MDT
Medtronic plc
 $119.00B -3.2% +8.4% 22.9 3.1%
SYK
Stryker Corp
 $116.76B -15.3% +11.2% 31.5 1.5%
BSX
Boston Scientific Corp
 $64.51B -53.3% +12.5% 18.0 2.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Short & Settlement
Short Interest Rising
Shares short
902
Days to cover
1.0d
Change
+599 sh
View
Short Volume
Short vol %
33%
As of
Oct 21, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$874
As of
Jan 7, 2026
View
Off-Exchange
Off-exchange %
100.0%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$2.7M
Net income (FY)
$-457.4K
EPS diluted
$0.02
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 12, 2026
This year
13
View
Exempt Offerings
Offering
$700.0K
Filed
Jan 6, 2026
View

Performance

5D 20D 120D MTD YTD
USAQ +21.5% +11.1% +17.8% +21.5% -35.9%
SPY +0.5% +0.7% +7.6% +1.4% +13.4%
vs SPY +21.0% +10.4% +10.2% +20.1% -49.2%
Key facts CIK 856984 Visit website Investor relations